Portage Biotech (NASDAQ:ALP) CEO Brittany Kaiser Buys 9,350 Shares of Stock

Posted by on Sep 14th, 2026

Portage Biotech Inc. (NASDAQ:ALP – Get Free Report) CEO Brittany Kaiser bought 9,350 shares of the firm’s stock in a transaction on Wednesday, September 9th. The shares were bought at an average cost of $5.35 per share, with a total value of $50,022.50. Following the transaction, the chief executive officer directly owned 16,766 shares of the company’s stock, valued at approximately $89,698.10. This trade represents a 126.08% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Portage Biotech Stock Performance

Shares of ALP stock opened at $4.04 on Monday. Portage Biotech Inc. has a 12 month low of $3.20 and a 12 month high of $690.00. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01. The business’s 50 day moving average is $10.78 and its two-hundred day moving average is $14.86. The company has a market cap of $6.26 million, a PE ratio of -0.49 and a beta of 0.54.

Portage Biotech (NASDAQ:ALP – Get Free Report) last issued its quarterly earnings data on Thursday, July 16th. The company reported $23.75 earnings per share for the quarter. The firm had revenue of $0.05 million during the quarter. Equities analysts predict that Portage Biotech Inc. will post -14 EPS for the current year.

Analyst Ratings Changes

Several brokerages recently commented on ALP. Weiss Ratings reiterated a “sell (e+)” rating on shares of Portage Biotech in a report on Friday, July 24th. Zacks Research raised Portage Biotech to a “hold” rating in a research report on Tuesday, August 18th. HC Wainwright assumed coverage on Portage Biotech in a research note on Monday, August 17th. They issued a “neutral” rating and a $12.50 price objective on the stock. Finally, Wall Street Zen upgraded Portage Biotech to a “hold” rating in a research note on Saturday. Two investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Portage Biotech has an average rating of “Reduce” and a consensus price target of $12.50.

View Our Latest Research Report on ALP

Portage Biotech Company Profile

(Get Free Report)

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.

See Also

Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.